Flamel Technologies (NASDAQ: AVDL) and Acura Pharmaceuticals (NASDAQ:ACUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Earnings and Valuation
This table compares Flamel Technologies and Acura Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Flamel Technologies||$173.99 million||2.05||$64.86 million||$0.84||10.26|
|Acura Pharmaceuticals||$6.96 million||N/A||-$2.50 million||($0.83)||-0.57|
Flamel Technologies has higher revenue and earnings than Acura Pharmaceuticals. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Flamel Technologies, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
71.0% of Flamel Technologies shares are owned by institutional investors. Comparatively, 31.2% of Acura Pharmaceuticals shares are owned by institutional investors. 5.1% of Flamel Technologies shares are owned by company insiders. Comparatively, 7.4% of Acura Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Flamel Technologies and Acura Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for Flamel Technologies and Acura Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Flamel Technologies presently has a consensus price target of $15.67, suggesting a potential upside of 81.75%. Acura Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 1,602.13%. Given Acura Pharmaceuticals’ higher possible upside, analysts plainly believe Acura Pharmaceuticals is more favorable than Flamel Technologies.
Risk & Volatility
Flamel Technologies has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500.
Flamel Technologies beats Acura Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Flamel Technologies
Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
What are top analysts saying about Flamel Technologies S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flamel Technologies S.A. and related companies.